PMID- 21426238
OWN - NLM
STAT- MEDLINE
DCOM- 20110914
LR  - 20171116
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 12
IP  - 9
DP  - 2011 Jun
TI  - Combination therapy with statin and fibrate in patients with dyslipidemia 
      associated with insulin resistance, metabolic syndrome and type 2 diabetes 
      mellitus.
PG  - 1429-38
LID - 10.1517/14656566.2011.563506 [doi]
AB  - INTRODUCTION: People with insulin resistance/metabolic syndrome (IR/MS) and/or 
      type 2 diabetes mellitus (T2DM) have increased rates of cardiovascular disease 
      (CVD) even when low-density lipoprotein cholesterol levels are at or near target 
      levels. Contributors to this problem are the high triglyceride (TG) levels and 
      low levels of high-density lipoprotein cholesterol (HDLC) that are commonly 
      present in this population, even with statin therapy. AREAS COVERED: This review 
      focuses on the use of a combination of statins with fibrates, which lower TG and 
      raise HDLC concentrations and, therefore, have the potential to further lower 
      rates of CVD more in people with IR/MS and/or T2DM. Treatment with this 
      combination is uncommon because doctors and patients are fearful of muscle, liver 
      and renal complications and because the evidence that the combination will 
      actually reduce risk has been lacking. In this review, the authors examine the 
      efficacy and safety of the statin-fibrate combination, particularly fenofibrate 
      and simvastatin, the combination used in the ACCORD trial. EXPERT OPINION: The 
      authors' opinion is that this combination of fenofibrate and statin is as safe as 
      either drug alone and, in patients with significant dyslipidemia, is likely to 
      reduce CVD. Concerns remain concerning fenofibrate-associated increases in serum 
      creatinine levels and the significant heterogeneity in the reduction in CVD by 
      the combination in women. A trial of statin + fenofibrate in people with IR/MS 
      and/or T2DM who also have significant dyslipidemia is needed.
FAU - Reyes-Soffer, Gissette
AU  - Reyes-Soffer G
AD  - Columbia University College of Physicians and Surgeons, Department of Medicine, 
      NY 10032, USA.
FAU - Rondon-Clavo, Carlos
AU  - Rondon-Clavo C
FAU - Ginsberg, Henry N
AU  - Ginsberg HN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110323
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Fibric Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
SB  - IM
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Dyslipidemias/blood/*drug therapy
MH  - Fibric Acids/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Insulin Resistance
MH  - Metabolic Syndrome/blood/*drug therapy
EDAT- 2011/03/24 06:00
MHDA- 2011/09/15 06:00
CRDT- 2011/03/24 06:00
PHST- 2011/03/24 06:00 [entrez]
PHST- 2011/03/24 06:00 [pubmed]
PHST- 2011/09/15 06:00 [medline]
AID - 10.1517/14656566.2011.563506 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2011 Jun;12(9):1429-38. doi: 
      10.1517/14656566.2011.563506. Epub 2011 Mar 23.